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Summary Current therapeutic guidelines for chronic heart failure (HF) recommend high (if
possible, maximum) target doses of angiotensin-converting enzyme (ACE) inhibitors and beta-
blockers. This is based on ‘‘evidence’’ from large-scale trials in selected patient populations.
In ‘‘real life’’, however, many patients receive doses below deﬁned targets, which is usually
classiﬁed as ‘‘under-treatment’’. When considering whether everyday practice is suboptimal,
an important question arises: is more always better and should dosage recommendations be
followed in all patients? The superiority of high vs. low-to-moderate doses of ACE inhibitors and
beta-blockers in reducing mortality from chronic HF has not been documented convincingly. In
large trials with beta-blockers, the efﬁcacy of below-target doses was not signiﬁcantly different
from that of high doses. With high-dose lisinopril, a reduction in the rate of hospitalizations was
achieved at the cost of more adverse events. A combination of ACE inhibitors and angiotensin
receptor blockers in chronic HF may also cause more problems than beneﬁts. The risks of high
doses of spironolactone, digoxin and diuretics are well-known. Sicker elderly and multimorbid
patients often do not tolerate the recommended targets but can still have a good clinical
response with an improved outcome at lower doses. Therefore lower-than-target doses may
not necessarily be wrong in certain patients and are better than ‘‘no doses’’, for example,
failure to prescribe essential heart-failure drugs. Individualized doses of ACE inhibitors and
beta-blockers (best in combination) are indicated in most patients with chronic HF. Less rigid
application of guideline recommendations may improve their acceptance.
© 2009 Elsevier Masson SAS. All rights reserved.
Abbreviations: ACE, angiotensin-converting enzyme; HF, heart failure.
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Résumé Les recommandations de traitement de l’insufﬁsance cardiaque préconisent la
prescription de fortes doses des inhibiteurs de l’enzyme de conversion et des bêtablo-
quants, doses-cibles atteintes dans les grandes études de mortalité. Cependant, dans la
pratique clinique quotidienne,la posologie de ces médicaments reste nettement plus faible, et
donc « non-optimale ». Pour cette raison des questions persistent : est-ce que la supériorité des
fortes doses est documentée de fac¸on convaincante et peut-on généraliser la posologie recom-
mandée à tous les patients en insufﬁsance cardiaque ? Un effet signiﬁcativement supérieur des
fortes doses comparativement aux faibles doses ou moyennes des bêtabloquants ou des inhib-
iteurs de l’enzyme de conversion sur le critère de mortalité n’est pas établi dans les études.
Les doses élevées de lisinopril réduisent le taux d’hospitalisation au prix cependant d’effets
secondaires plus fréquents. Il existe aussi un risque accru d’effets indésirables avec l’association
inhibiteurs de l’enzyme de conversion et antagonistes des récepteurs de l’angiotensine II. Les
problèmes de surdosage des diurétiques, spironolactone et digoxine sont bien connus. Il faut
reconnaître que les sujets âgés et porteurs de morbidités multiples, qui représentent la majorité
des malades ayant une insufﬁsance cardiaque, souvent ne tolèrent pas les doses cibles recom-
mandées. Néanmoins, un effet thérapeutique peut être atteint même avec les doses moindres.
Les inhibiteurs de l’enzyme de conversion et les bêtabloquants devraient être prescrits chez tous
les patients ayant une insufﬁsance cardiaque, mais une adaptation individuelle de la posologie
est indispensable chez les patients âgés.
© 2009 Elsevier Masson SAS. Tous droits réservés.
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Ahe goals of modern treatment in chronic heart failure
HF) are rapid relief of symptoms and reduction in rates of
ortality and hospitalizations. Based on data from large-
cale, multicentre trials, European [1] and US [2] guidelines
ist angiotensin-converting enzyme (ACE) inhibitors and
eta-blockers as ﬁrst-line drugs. It is recommended to
ptitrate the doses of these drugs to high target lev-
ls as deﬁned in the original trial protocols, assuming a
uperior efﬁcacy compared with lower doses. Adherence
o the guidelines in ‘‘real life’’ is, however, still disap-
ointing, not only by generalists [3] but also cardiologists
4,5]. In particular, beta-blockers are prescribed less fre-
uently than indicated and the average doses of both of
hese important drugs usually remain below the recom-
endations. This practice is regarded as an indication of
idespread ‘‘under-treatment’’ of chronic HF patients [6]
nd various measures are suggested to correct the situ-
tion. The gap between guideline recommendations and
linical routine is an important issue; suboptimal treat-
ent should be avoided by all physicians involved in the
are of patients with chronic HF. There are several argu-
ents against an uncritical and dogmatic enforcement of
he guideline recommendations and a disregard of the spe-
ial characteristics of certain patient sub-populations. The
im of this review is to critically re-examine this question:
re low doses of ACE inhibitors and beta-blockers really
ess effective and is a higher dose of a HF drug always
etter?
rgument 1he ‘‘landmark’’ trials do not provide a sufﬁcient evidence
ase for the treatment of elderly patients with comor-
idities, who comprise a major part of the chronic HF
opulation. Patients included in the clinical trials were
T
h
v
psually men aged less than 70 years with systolic left ven-
ricular dysfunction, coronary artery disease but no renal
ailure, coexisting chronic lung disease or systolic blood
ressure less than 120mmHg. In contrast, in recent HF epi-
emiological surveys [7—9], the patients’ mean age was
ore than 70 years, around 50% were women, and they had
preserved left ventricular ejection fraction and several
elevant comorbid conditions (Table 1). Thus, the results
f the main studies with ACE inhibitors and beta-blockers,
specially the dosage used, cannot be extrapolated to other
ypes of patients.
rgument 2
he predeﬁned high target doses were not always reached
nd maintained, even in the selected trial populations
Table 2) [10—13]. Not surprisingly, in a large proportion
f ambulatory and hospital patients, the ACE inhibitor and
eta-blocker doses remained below 50% of the deﬁned
argets (Table 3) [3,14]. The difﬁculty in up-titrating the
arvedilol dose in a consecutive series of 100 patients has
een described well by Mehta et al. [15]. Experience from
linical practice indicates a sometimes unrealistic expec-
ation of HF specialists regarding the practicability of the
osage recommendations in the guidelines. We may have
o consider a more ﬂexible and individualized approach to
reatment.
rgument 3he decisive question relates to the assumed superiority of
igh doses of ACE inhibitors and beta-blockers. Is there con-
incing evidence to accept the routine application of the
roposed targets as a quality standard?
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Table 1 Comparison of patient characteristics in randomized trials vs. clinical surveys.
Drug Mean age (years) Men/women (%) CAD (%) Exclusion for comorbidities
Trials [ref]
SOLVD [10] Enalapril 60.9 81/19 70 RD, PD and any relevant disease
ATLAS [16] Lisinopril 63.6 79/21 64 RD and any relevant disease
CIBIS II [11] Bisoprolol 61.0 81/19 50 RD, LD
MERIT-HF [12] Metoprolol 63.9 77/23 65 RD and any relevant disease
COPERNICUS [13] Carvedilol 63.2 79/21 67 RD, PD, LD
Surveys [ref] Comorbidities
IMPROVEMENT [8] ND 70 55/45 57 RD 19%, PD 31%, TIA 16%, D 20%
EURO-HF I [7] ND 71 57/43 68 RD 17%, PD 32%, TIA 10%, D 27%
ATLAS: assessment of treatment with lisinopril and survival; CAD: coronary artery disease; CIBS II: Cardiac Insufﬁciency Bisoprolol Study
II; COPERNICUS: carvedilol prospective randomized cumulative survival; D: diabetes; LD: liver disease; PD: pulmonary disease; MERIT-HF:
Metoprolol CR/XL Randomized Intervention Trial in Heart Failure; ND: not deﬁned; RD: renal disease (elevated serum creatinine); ref:
reference; RLD: relevant disease; SOLVD: studies of left ventricular dysfunction; TIA: transient ischemic attack.
Table 2 Mean doses vs. target doses in clinical trials with ACE inhibitors and beta-blockers.
Trial [ref] Drug Mean dose (mg/day) Target dose (mg/day)
SOLVD [10] Enalapril 11.2 20
CIBIS II [11] Bisoprolol 7 10
MERIT-HF [12] Metoprolol — 200
COPERNICUS [13] Carvedilol 37 50
ACE: angiotensin-converting enzyme; CIBS II: Cardiac Insufﬁciency Bisoprolol Study II; COPERNICUS: carvedilol prospective randomized
terve
w
h
t
o
(
h
a
ocumulative survival; MERIT-HF: Metoprolol CR/XL Randomised In
dysfunction.
The ﬁrst randomized dose comparison with enalapril was
carried out by the NETWORK investigators [16], assessing
the outcome in primary care and hospitalized patients with
symptomatic chronic HF. During a relatively short follow-up
of 24 weeks, there were no signiﬁcant differences in the
risks of death, hospitalization for HF or worsening HF with
doses of 2.5mg, 5mg and 10mg enalapril, each given twice
daily.The main reason for recommending a maximized dosage
comes from the Assessment of Treatment with Lisinopril and
Survival (ATLAS) Trial [17], which compared the outcomes in
more than 3000 patients observed for at least three years,
c
a
p
p
Table 3 Drug dosage in the ESC guidelines [13] and the EuroH
Drug ESC guidelines
ACE inhibitor
Captopril 25—50mg tid
Enalapril 10mg bid
Lisinopril 5—20 mg/day
Ramipril 2.5 —5mg bid
Beta-blocker
Bisoprolol 10 mg/day
Metoprolol CR 200 mg/day
Carvedilol 50 mg/day
ACE: angiotensin-converting enzyme; bid: twice daily; ESC: European Sntion Trial in Heart Failure; SOLVD: studies of left ventricular
ho were receiving treatment with low (2.5—5mg/day) or
igh (32.5—35mg/day) doses of lisinopril. At the end of
he study, there was no signiﬁcant difference in all cause
r cardiovascular mortality, but a 12% lower relative risk
p = 0.002) of the composite endpoint of total mortality plus
ospitalization for any reason. Hospitalizations for HF were
lso reduced by 24%. However, these relative advantages
f high-dose lisinopril were achieved at the cost of signiﬁ-
antly more adverse events, such as hypotension, dizziness
nd worsening renal function. It should also be noted that
atients with poor tolerance of lisinopril during a run-in
hase were excluded before randomization. More recently,
eart Failure Survey [3,14].
EuroHeart Failure Survey
57.5 ± 37.1 mg/day
14.3 ± 9.1 mg/day
12.3 ± 7.8 mg/day
5.1 ± 3.0 mg/day
4.7 ± 2.6 mg/day
74.9 ± 43.3 mg/day
17.6 ± 16.6 mg/day
ociety of Cardiology; tid: three times daily.
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Figure 2. Relationship between heart rates achieved by low and
high doses of controlled-release metoprolol in the MERIT-HF trial
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Cigure 1. Relative risks and 95% conﬁdence intervals for mortal-
ty in low-dose and high-dose metoprolol patient subgroups in the
ERIT-HF trial [19].
opyright licence number 2223550835401, obtained from Elsevier.
meta-analysis of HF trials testing the combination of
CE inhibitors plus angiotensin receptor blockers showed
o clear clinical advantages of intensiﬁed blockade of the
enin-angiotensin-aldosterone system, but again conﬁrmed
he increased risks of symptomatic hypotension, worsening
enal function and hyperkalaemia [18].
The lack of superior efﬁcacy of high vs. moderate-to-
ow doses of beta-blockers has been well documented in
he two major trials with metoprolol and bisoprolol. In the
etoprolol CR/XL Randomized Intervention Trial in MERIT-
F [19], the reduction in total mortality, sudden death
nd death from worsening HF was in the same range in
atients receiving more than 100mg metoprolol succinate
nd in those tolerating only less than 100mg daily (Fig. 1).
most important ﬁnding in this trial was a faster and
ore marked reduction of heart rate ≤ 70 beats/min in
he low-dose subgroup, indicating a greater sensitivity to
he beta-blocking effects (Fig. 2). A similar outcome was
eported in a secondary analysis of the Cardiac Insufﬁciency
isoprolol Study II (CIBIS II) [20], showing signiﬁcant and
imilar relative reductions in mortality by low (< 5mg), mod-
rate (5—7.5mg) and high (10mg) daily doses of bisoprolol
s. the corresponding randomized placebo groups.
In addition to the ACE inhibitor and beta-blocker trials
entioned above, there are also well-known data docu-
enting increased risks with higher doses of digoxin [21],
iuretics [22] and spironolactone [23].
Hence, it can be concluded that more is not always better
n the drug treatment of patients with HF.rgument 4
ould it be that an apparently better survival trend in
atients who tolerate the higher targets is not due directly
o the dose levels achieved but to the selection of patients
A
e
c
p19].
opyright licence number 2223550835401, obtained from Elsevier.
ith a lower overall risk and a better prognosis? There are
everal observations suggesting that this theory may be true.
reduced dose tolerance of bisoprolol in CIBIS II [20] was
ssociated with more advanced HF, older age, lower sys-
olic and diastolic blood pressures, severe arrhythmias and
eft bundle branch block, all of which are predictors of a
orse outcome. Similar reasons for intolerance of metopro-
ol doses greater than 100mg were found in the low-dose
ubgroup of patients in the MERIT-HF trial [19]. Such patient
haracteristics could also explain some of the differences
etween rates of prescription of the main HF drugs by cardi-
logists and general internists. Cardiologists prescribe more
CE inhibitors and beta-blockers and use higher doses than
eneralists, but the patient populations managed by the two
roups of specialists belong to quite different risk groups
24].
Advanced age is probably the most important limiting
actor for dose titration to higher levels. In the recently
ublished Trial of Intensiﬁed vs. Standard Medical Therapy
n Elderly Patients with Congestive Heart Failure (TIME-
HF) Trial [25], a treatment selected according to brain
atriuretic peptide levels was compared with standard man-
gement in patients aged less than 75 years and more than
5 years. A higher average dose of ACE inhibitors and beta-
lockers achieved in the brain natriuretic peptide-guided
ubgroup did not improve the clinical outcome and was asso-
iated with a poorer quality of life in the older age group
more than 75 years).
onclusionsguideline-recommended choice of drugs remains the sci-
ntiﬁcally validated basis for treatment in all patients with
hronic HF. Beta-blockers and ACE inhibitors can improve
rognosis and reduce rates of hospitalization even in the
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elderly. The additive therapeutic effects of these agents are,
therefore, usually beneﬁcial, regardless of age and comor-
bid conditions. However, instead of insisting on high target
doses, the dose should be adapted individually, consider-
ing renal function, blood pressure, concomitant treatments
and other conditions. Very low initial doses and slower up-
titration will improve the tolerance and acceptance of HF
drugs by elderly patients. Close observation of patients,
with repeated careful clinical examinations to detect early
signs of adverse reactions, will allow therapeutic goals to
be reached, even if doses lower than the recommended tar-
gets are used. A dogmatic approach to treatment regimens
does not always produce a general advantage in all types of
chronic HF patients.
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